Suana, A J; Tuffin, G; Frey, B M; Knudsen, L; Mühlfeld, C; Rödder, S; Marti, H-P (2011). Single application of low-dose mycophenolate mofetil-OX7-immunoliposomes ameliorates experimental mesangial proliferative glomerulonephritis. Journal of pharmacology and experimental therapeutics, 337(2), pp. 411-22. Bethesda, Md.: American Society for Pharmacology and Experimental Therapeutics 10.1124/jpet.110.176222
Full text not available from this repository.IgA nephropathy, one of the most frequent forms of glomerulonephritis, characterized by mesangial hypercellularity and glomerular extracellular matrix (ECM) expansion, often leads to end-stage renal disease over a prolonged period. We investigated whether antiproliferative treatment in a single low dose specifically targeted to the glomerular mesangium by immunoliposomes (ILs) results in an amelioration of mesangial proliferative glomerulonephritis in rats (anti-Thy1.1 nephritis). Mycophenolate mofetil (MMF) containing ILs was generated that targets the Thy1.1 antigen (OX-7) in rat mesangial cells. Treatment benefit of a single intravenous dose of these ILs given 2 days after disease induction was investigated by stereology, immunohistochemistry, and functional analyses (creatinine, albuminuria) until day +9 and was compared among untreated and free MMF-treated rats using six male Wistar rats per group. MMF-loaded OX7-IL prevented creatinine increase and albuminuria. Stereological analyses of MMF OX7-IL-treated animals yielded 30% reduction of mesangial cells on day +9 and a 40% reduction of glomerular ECM volume on day +5, compared with all of the other nephritic animals. Furthermore, at days +5 and +9 we observed decreased ECM content and decreased glomerular volume (day +5) in the MMF-OX7-IL-treated group compared with the nephritic group treated with free MMF. In conclusion, MMF-OX7-IL-based directed drug delivery represents a novel approach for treating mesangial cell-mediated forms of glomerulonephritis.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Nephrology and Hypertension |
UniBE Contributor: |
Marti, Hans-Peter |
ISSN: |
0022-3565 |
Publisher: |
American Society for Pharmacology and Experimental Therapeutics |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:25 |
Last Modified: |
05 Dec 2022 14:07 |
Publisher DOI: |
10.1124/jpet.110.176222 |
PubMed ID: |
21349934 |
Web of Science ID: |
000289671600009 |
URI: |
https://boris.unibe.ch/id/eprint/8976 (FactScience: 214636) |
Actions (login required)
 |
Edit item |